Bladder cancer study digs into Real-World treatment decisions
NCT ID NCT07339878
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at why some people with advanced bladder cancer receive older platinum-based chemotherapy instead of a newer, more effective drug combination. Researchers will review the medical records of 50 patients to understand the reasons behind these treatment choices. The goal is to learn more about patient characteristics and decision-making in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service Oncologie Médicale - CHU de Strasbourg - France
RECRUITINGStrasbourg, 67091, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New drug option for Hard-to-Treat cancers with FGFR3 mutations
- New bladder cancer drug aims to fight tumors without harming nerves
- New hope for advanced bladder cancer? bevacizumab combo tested
- New cocktail of drugs takes on Hard-to-Treat bladder cancer
- New imaging tracer could spot hidden cancers